Ondansetron

Late intrauterine deaths (> 22 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S2778
R4606		 Fejzo (Mainly exposed to other treatements, sick), 2016 Stillbirths (21-36 and 37-40 weeks) / Neonatal death 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 1.30 [0.43;3.89] C
excluded (control group) 		9/1,070   5/771 14 1,070
ref
S2776
R4607		 Fejzo (Unexposed control, disease free), 2016 Stillbirths (21-36 and 37-40 weeks) 1st trimester retrospective cohort unexposed, disease free Adjustment: No 1.19 [0.49;2.88] C 9/1,070   11/1,555 20 1,070
ref
S2775
R3715		 Colvin, 2013 Stillbirth during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.80 [0.60;5.50] -/263   635/98,062 626 263
ref
S2746
R3637		 Pasternak, 2013 Stillbirth (fetal loss after 22 weeks of gestation) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.42 [0.10;1.73] 6/1,915   27/7,660 33 1,915
ref
S2755
R3668		 Einarson (Control exposed to other antiemetics), 2004 Stillbirth (NOS) 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.33 [0.01;8.19] C
excluded (control group) 		0/176   1/176 1 176
ref
S2754
R3664		 Einarson (Unexposed control), 2004 Stillbirth (NOS) 1st trimester prospective cohort unexposed, disease free Adjustment: No 1.00 [0.02;50.68] C 0/176   0/176 0 176
ref
Total 4 studies 1.11 [0.60;2.05] 679 3,424
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Fejzo (Unexposed control, disease free), 2016Fejzo, 2016 1 1.19[0.49; 2.88]201,07048%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Colvin, 2013Colvin, 2013 1.80[0.60; 5.50]62626331%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Pasternak, 2013Pasternak, 2013 0.42[0.10; 1.73]331,91519%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Einarson (Unexposed control), 2004Einarson, 2004 2 1.00[0.02; 50.68]01762%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 0% 1.11[0.60; 2.05]6793,4240.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Unexposed control, disease free; 2: Unexposed control;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.11[0.60; 2.05]6793,4240%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Pasternak, 2013 Einarson (Unexposed control), 2004 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.11[0.60; 2.05]6793,4240%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Pasternak, 2013 Einarson (Unexposed control), 2004 4 Tags Adjustment   - No  - No 1.38[0.70; 2.73]6461,5090%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Einarson (Unexposed control), 2004 3   - Yes  - Yes 0.42[0.10; 1.75]331,915 -NAPasternak, 2013 1 All studiesAll studies 1.11[0.60; 2.05]6793,4240%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Pasternak, 2013 Einarson (Unexposed control), 2004 40.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.74.82.4030.000Fejzo (Unexposed control, disease free), 2016Colvin, 2013Pasternak, 2013Einarson (Unexposed control), 2004

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 2755, 2778

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.11[0.60; 2.05]6793,4240%NAFejzo (Unexposed control, disease free), 2016 Colvin, 2013 Pasternak, 2013 Einarson (Unexposed control), 2004 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.13[0.40; 3.18]151,2460%NAFejzo (Mainly exposed to other treatements, sick), 2016 Einarson (Control exposed to other antiemetics), 2004 20.510.01.0